The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
DaProphet,
Do you have access to LSE L2.
If so you can check this. At the moment all the buys and sells are colour coded in red.
Final fantasy also bought 10993@72.60p as well.
Please don’t write and say comical and ramping.
These are factual information.
Say sorry for your post.
bbrq648
Please find attached the tweet by Prof. Carl Smythe about Paraytec Fast and Effective Test, and tweeted,”I rather think that the English Football League @EFL_Comms need to hear about our fast and effective test.
No need for a passport when you can test on the spot.”
What is the hold-up?
Expect an RNS sooner than later.
bbrq648
The deficiencies of the LFT and RT-PCR tests have been known to Paraytec and Prof. Carl Smythe and his team.
During the Fast track Paraytec LFT and Multiplex Matrix Test Development, the Test performance to take into consideration of sensitivity and specificity as well as the presence of level of viral load to lower levels to pick-up pre-symptomatic and asymptomatic persons are identified and isolated in advance to stop spreading the COVID-19 viruses in public places.
As the symptomatic cases have high viral load had good detection with false negative and false positives. These issues were also addressed during the BRH Test development.
Furthermore, proper sampling techniques put in place to identify tests are invalid cases, and to repeat the test. This will be addressed in the sampling technique to be used for both the tests.
DHSC had tightened the testing ranges and viral loads to pick-up pre-symptomatic and a symptomatic cases more accurately in their latest specification.
BRH RNS dated 01-Mar-2021 & 26-Mar-2021 clearly stated the interim trial test conducted, and refined as appropriate to meet or exceed the DHSC specific requirements.
Thus, even with the delay in testing and with additional platform technology to potentially identify/ detect multiple virus targets will be the only market leader in Fast, Accurate and Sensitive test available very soon.
Forecast date: End of April 2021.
Even with a month delay, this BRH/Paraytec Test is going to be the market leader.
With UKCA, CE, FDA approvals, PHA Test Validation, Approvals, Partner(s), Manufacturers licences and Contracts are still outstanding and will be forthcoming in successive RNSs from BRH/Paraytec.
Start buying, and keep it tugged away for the share price to move back to £1.40 and then gradually move northward (increase).
By then the Alzheimer’s and Sepsis Tests would progress successfully to further increase in BRH share value.
Good Luck to LTH.
bbrq648
Driving up standards and removing poor performing tests for both LFT and PCR will lead the way for more new investors buying BRH shares tomorrow.
Expectations will be high, with this in mind, any news with RNS will escalate the share price higher.
Watch the space.
bbrq648
The deficiencies of the LFT and RT-PCR tests have been known to Paraytec and Prof. Carl Smythe and his team.
During the Fast track Paraytec LFT and Multiplex Matrix Test Development, the Test performance to take into consideration of sensitivity and specificity as well as the presence of level of viral load to lower levels to pick-up pre-symptomatic and asymptomatic persons are identified and isolated in advance to stop spreading the COVID-19 viruses in public places.
As the symptomatic cases have high viral load had good detection with false negative and false positives. These issues were also addressed during the BRH Test development.
Furthermore, proper sampling techniques put in place to identify tests are invalid cases, and to repeat the test. This will be addressed in the sampling technique to be used for both the tests.
DHSC had tightened the testing ranges and viral loads to pick-up pre-symptomatic and a symptomatic cases more accurately in their latest specification.
BRH RNS dated 01-Mar-2021 clearly stated the interim trial test conducted, and refined as appropriate to meet or exceed the DHSC specific requirements.
Thus, even with the delay in testing and with additional platform technology to potentially identify/ detect multiple virus targets will be the only market leader in Fast, Accurate and Sensitive test available very soon.
Forecast date: End of April 2021.
Even with a month delay, this BRH/Paraytec Test is going to be the market leader.
With UKCA, CE, FDA approvals, PHA Test Validation, Approvals, Partner(s), Manufacturers licences and Contracts are still outstanding and will be forthcoming in successive RNAs from BRH/Paraytec.
Start buying, and keep it tugged away for the share price to move back to £1.40 and then gradually move northward (increase).
By then the Alzheimer’s and Sepsis Tests would progress successfully to further increase in BRH share value.
Good Luck to LTH.
bbrq648
edy007,
Thanks for your response. TB still holds approximately 75% ( 5,424,562 shares) and is the biggest share holder of BRH.
Have you invested previously in any shares?
Don’t you know directors sell and buy shares in their own Company?
This is normal, and why you are so concerned.
How many shares did you buy on 05-Mar-2021?
If you are LTH you would not have raised this as an issue.
Only rerampers and bashers try and post like this to manipulate the shares to either buy at a lower price or worrying investment in another Competitor Company.
As you are a BRH investor, just hold your shares and watch patiently for several stepwise RNS to get posted and stepwise steady increase in BRH share price.
bbrq648
DaProphet,
Your statement “new breed will be surescreen/ avacta/ mologic/ visiteck in the next few weeks” don’t tally with Castlepaul statement of 3 out of 40 have passed first assessment.
Please explain.
bbrq648